Clinical Scorecard: ACS report: Lung cancer deaths plunge as survival doubles
At a Glance
| Category | Detail |
|---|---|
| Condition | Lung Cancer |
| Key Mechanisms | Decline in smoking prevalence, increased screening uptake, and improved access to treatment. |
| Target Population | Adults eligible for lung cancer screening. |
| Care Setting | Population-based cancer registries and health statistics. |
Key Highlights
- Lung cancer mortality decreased 52% among males and 37% among females from 2004 to 2023.
- Five-year relative survival for lung cancer doubled from 15% in 2000 to 30% in 2018.
- Lung cancer incidence decreased by 38% among males and 15% among females from 2003 to 2022.
- Adult cigarette smoking prevalence declined 56% from 2001 to 2024.
- Proportion of lung cancers diagnosed at a localized stage increased from 16% to 27% among males.
Guideline-Based Recommendations
Diagnosis
- Increased screening uptake for eligible adults.
Management
- Access to guideline-concordant treatment.
Monitoring & Follow-up
- Continued tobacco prevention and cessation efforts.
Risks
- Incomplete or inaccurate recording of race or Hispanic origin may affect findings.
Patient & Prescribing Data
Adults eligible for lung cancer screening.
Comprehensive biomarker testing is recommended.
Clinical Best Practices
- Sustain progress through tobacco prevention and cessation.
- Promote increased screening uptake.
- Ensure access to guideline-concordant treatment.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
